Project Grant R01DK149400
Award Date 8/10/26
Completion Date 4/30/30
Dollars Obligated $651K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70112, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Administrators of Tulane Educational Fund (doing business as Tulane University) $673,261 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate hematopoietic stem cell response to chronic liver disease and their role in systemic inflammation. The research addresses mechanisms by which chronic liver injury disrupts bone marrow homeostasis,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1,677,898 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop fat and iron-corrected quantitative MRI T1 mapping as a non-invasive biomarker for evaluating chronic liver disease, particularly metabolic-associated steatohepatitis (MASH). The project addresses the clinical need for non-invasive assessment of liver pathology...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $874,741 on June 1, 2026, to investigate transcriptional mechanisms of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research identifies and characterizes transcription factors that regulate collagen production in hepatic stellate cells, a key driver of liver...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $639,990 to The University of Texas Health Science Center at San Antonio on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant R01DK144299). The recipient will investigate the role of oxidized phospholipids (OXPLs) in driving metabolic dysfunction-associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC). Research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $743,862 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on macrophage mitochondrial metabolism and metabolic dysfunction-associated steatotic liver disease (MASLD). The research investigates how alterations in macrophage composition and function contribute to MASH (metabolic dysfunction-associated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $889,856 on August 17, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms by which metabolic-associated fatty liver disease (MASH) drives chronic kidney disease pathogenesis. The recipient will conduct three specific research aims over the performance period through April 30, 2031. Aim 1 confirms the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $850,096 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of S100A9+ macrophages and monocytic myeloid-derived suppressor cells in driving liver fibrosis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). The research leverages advanced multi-omics...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Southwestern Medical Center $694,250 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to explore a novel pathway for ApoB mRNA degradation in regulating VLDL secretion and steatotic liver disease. The recipient will conduct basic biomedical research identifying mechanisms by which the HELZ2 gene regulates hepatic lipid secretion...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Seattle Institute for Biomedical and Clinical Research $272,400 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to execute target trial emulation studies comparing the effectiveness of pharmacotherapies and bariatric surgery for metabolic dysfunction associated steatohepatitis (MASH). The award funds high-quality observational studies using the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Board of Regents of the University of Nebraska $529,273 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the MATRIN3-CAR-thrombin axis in hepatic inflammation and fibrosis. The research addresses metabolic dysfunction-associated steatotic liver disease (MASLD), which affects approximately 30 percent of U.S. adults and can progress to...